WEKO3
アイテム
Development of Antibody–Drug Conjugates Using DDS and Molecular Imaging
https://repo.qst.go.jp/records/48406
https://repo.qst.go.jp/records/48406f1dbf7bc-8bcc-40c7-9643-0ca46210d1ea
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2017-12-06 | |||||
| タイトル | ||||||
| タイトル | Development of Antibody–Drug Conjugates Using DDS and Molecular Imaging | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Yasunaga, Masahiro
× Yasunaga, Masahiro× Manabe, Shino× Tsuji, Atsushi× Tsuneo, Saga× 辻 厚至 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Antibody-drug conjugate (ADC), as a next generation of antibody therapeutics, is a combination of an antibody and a drug connected via a specialized linker. ADC has four action steps: systemic circulation, the enhanced permeability and retention (EPR) effect, penetration within the tumor tissue, and action on cells, such as through drug delivery system (DDS) drugs. An antibody with a size of about 10 nm has the same capacity for passive targeting as some DDS carriers, depending on the EPR effect. In addition, some antibodies are capable of active targeting. A linker is stable in the bloodstream but should release drugs efficiently in the tumor cells or their microenvironment. Thus, the linker technology is actually a typical controlled release technology in DDS. Here, we focused on molecular imaging. Fluorescent and positron emission tomography (PET) imaging is useful for the visualization and evaluation of antibody delivery in terms of passive and active targeting in the systemic circulation and in tumors. To evaluate the controlled release of the ADC in the targeted area, a mass spectrometry imaging (MSI) with a mass microscope, to visualize the drug released from ADC, was used. As a result, we succeeded in confirming the significant anti-tumor activity of anti-fibrin, or anti-tissue factor-ADC, in preclinical settings by using DDS and molecular imaging. | |||||
| 書誌情報 |
Bioengineering 巻 4, 号 3, p. 78-1-78-13, 発行日 2017-09 |
|||||
| 出版者 | ||||||
| 出版者 | Multidisciplinary Digital Publishing Institut | |||||
| PubMed番号 | ||||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 28952557 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.3390/bioengineering4030078 | |||||
| 関連サイト | ||||||
| 識別子タイプ | URI | |||||
| 関連識別子 | https://www.ncbi.nlm.nih.gov/pubmed/?term=PMC5615324 | |||||
| 関連名称 | https://www.ncbi.nlm.nih.gov/pubmed/?term=PMC5615324 | |||||
